- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - indian pharma
- SUN PHARMA - MYLAN (US)
SUN PHARMA vs MYLAN (US) - Comparison Results
SUN PHARMA 
Change
Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More
MYLAN (US)
Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
Financials
 SUN PHARMA  MYLAN |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| SUN PHARMA Mar-18 |
MYLAN Dec-14 |
SUN PHARMA/ MYLAN |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 701 | 4,245 | - | |
| Low | Rs | 433 | 2,992 | - | |
| Sales per share (Unadj.) | Rs | 110.4 | 1,453.3 | - | |
| Earnings per share (Unadj.) | Rs | 11.0 | 175.1 | - | |
| Cash flow per share (Unadj.) | Rs | 17.2 | 281.8 | - | |
| Dividends per share (Unadj.) | Rs | 2.00 | 0 | - | |
| Dividend yield (eoy) | % | 0.4 | 0 | - | |
| Book value per share (Unadj.) | Rs | 158.8 | 722.4 | - | |
| Shares outstanding (eoy) | m | 2,399.26 | 378.37 | - | |
| Bonus/Rights/Conversions | - | OI | - | ||
| Price / Sales ratio | x | 5.1 | 2.5 | 206.2% | |
| Avg P/E ratio | x | 51.6 | 20.7 | 249.8% | |
| P/CF ratio (eoy) | x | 32.9 | 12.8 | 256.2% | |
| Price / Book Value ratio | x | 3.6 | 5.0 | 71.3% | |
| Dividend payout | % | 18.2 | 0 | - | |
| Avg Mkt Cap | Rs m | 1,360,021 | 1,369,126 | 99.3% | |
| No. of employees | `000 | 17.8 | 25.0 | 71.2% | |
| Total wages/salary | Rs m | 53,671 | 0 | - | |
| Avg. sales/employee | Rs Th | 14,890.9 | 21,995.8 | 67.7% | |
| Avg. wages/employee | Rs Th | 3,017.1 | 0 | - | |
| Avg. net profit/employee | Rs Th | 1,480.6 | 2,649.8 | 55.9% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 264,895 | 549,896 | 48.2% | |
| Other income | Rs m | 8,388 | -3,205 | -261.7% | |
| Total revenues | Rs m | 273,282 | 546,690 | 50.0% | |
| Gross profit | Rs m | 56,081 | 136,762 | 41.0% | |
| Depreciation | Rs m | 14,998 | 40,387 | 37.1% | |
| Interest | Rs m | 5,176 | 23,720 | 21.8% | |
| Profit before tax | Rs m | 44,295 | 69,449 | 63.8% | |
| Minority Interest | Rs m | 0 | -285 | 0.0% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | -9,505 | 0 | - | |
| Tax | Rs m | 8,452 | 2,920 | 289.4% | |
| Profit after tax | Rs m | 26,338 | 66,244 | 39.8% | |
| Gross profit margin | % | 21.2 | 24.9 | 85.1% | |
| Effective tax rate | % | 19.1 | 4.2 | 453.8% | |
| Net profit margin | % | 9.9 | 12.0 | 82.5% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 316,359 | 483,431 | 65.4% | |
| Current liabilities | Rs m | 198,643 | 377,946 | 52.6% | |
| Net working cap to sales | % | 44.4 | 19.2 | 231.7% | |
| Current ratio | x | 1.6 | 1.3 | 124.5% | |
| Inventory Days | Days | 95 | 78 | 121.5% | |
| Debtors Days | Days | 108 | 107 | 100.4% | |
| Net fixed assets | Rs m | 213,178 | 127,217 | 167.6% | |
| Share capital | Rs m | 2,399 | 19,446 | 12.3% | |
| Net worth | Rs m | 381,006 | 273,352 | 139.4% | |
| Long term debt | Rs m | 17,721 | 408,362 | 4.3% | |
| Total assets | Rs m | 643,028 | 1,101,038 | 58.4% | |
| Interest coverage | x | 9.6 | 3.9 | 243.3% | |
| Debt to equity ratio | x | 0 | 1.5 | 3.1% | |
| Sales to assets ratio | x | 0.4 | 0.5 | 82.5% | |
| Return on assets | % | 4.9 | 8.2 | 60.0% | |
| Return on equity | % | 6.9 | 24.2 | 28.5% | |
| Return on capital | % | 10.0 | 13.6 | 73.6% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 39,072 | 72,284 | 54.1% | |
| From Investments | Rs m | -33,708 | -57,005 | 59.1% | |
| From Financial Activity | Rs m | -15,393 | -19,047 | 80.8% | |
| Net Cashflow | Rs m | -7,359 | -3,768 | 195.3% | |
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 71.23 Rs / USD
Compare SUN PHARMA With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Compare SUN PHARMA With: PANACEA BIOTECH J.B.CHEMICALS MERCK LTD NATCO PHARMA STERLING BIOTECH
|
| |
Today's Market
Sensex Ends 404 Points Higher; Metal and Oil & Gas Stocks Witness Buying(Closing)
Indian share markets continued their momentum during closing hours and ended the day on a strong note. Gains were largely seen in the metal sector and oil & gas sector.
Related Views On News
SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)
Feb 13, 2019 | Updated on Feb 13, 2019For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)
Dec 20, 2018 | Updated on Dec 20, 2018Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)
Nov 14, 2018 | Updated on Nov 14, 2018For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)
Nov 20, 2017The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.
Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)
Aug 14, 2017A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.
More Views on NewsMost Popular
The RCom Bankruptcy: 5 Lessons for Smallcap Investors(Profit Hunter)
Feb 7, 2019Managements of companies can create or ruin their fortunes. Why is management quality such an important factor in valuing businesses? Read on to find out...
The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)
Feb 13, 2019The real estate sector is ready to make a comeback. This is the stock to consider buying.
How We Pick the Most Profitable Stocks from the Portfolios of Super Investors(The 5 Minute Wrapup)
Feb 8, 2019This is the trick to following super investors and not losing money.
Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)
Feb 14, 2019During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.
Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)
Feb 14, 2019Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.
More|
| |
SUN PHARMA SHARE PRICE
Feb 20, 2019 (Close)
TRACK SUN PHARMA
- Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON SUN PHARMA
SUN PHARMA 8-QTR ANALYSIS
COMPARE SUN PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.